Skip to main
NRSN

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics is well-positioned to take advantage of the growing market for neurodegenerative disease treatments with its promising product candidate, PrimeC. Their focus on targeting neuroinflammation and lysosomal dysfunction sets them apart in the industry, and their strategic decision to combine two generic drugs has the potential to carve out a significant market share. Along with a Buy rating and a $8 price target, NeuroSense has projected blockbuster potential with estimated sales of $1 billion and a 20% market penetration.

Bears say

NeuroSense Therapeutics is a financially sound company with a promising drug candidate in PrimeC, but their current timeline for FDA approval and launch in 2027 and 2028, respectively, may not be aligned with the urgent needs for new treatments for neurodegenerative diseases. Additionally, the company's reliance on strategic resources and potential changes to their drug candidate could pose risks to their overall success.

NRSN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 3 analysts, NRSN has a Strong Buy consensus rating as of Sep 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.